Fig. 5From: A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastropheSynergistic effect of DCZ3301 and BTZ in MM cell lines. Effect of treatment with BTZ alone- or in combination with different doses of DCZ3301 on cell growth in NCI-H929S (a), RPMI-8226 (b), NCI-H929R (c), and RPMI-8226R5 (d) cells. Combination index (CI) for two drugs in the MM cell lines. CI value < 1 represents synergistic. Data were expressed as mean ± SD. (e and f) Cell cycle analysis of BTZ-resistant MM cells treated with DCZ3301 alone, BTZ alone, and in combination with DCZ3301. (g) Western blot of G2/M phase related proteins in NCI-H929R and RPMI-8226R5 cells treated with DCZ3301 alone, BTZ alone and their combination for 48 hBack to article page